Aurinia Pharmaceuticals Inc. Increase (Decrease) in Receivables
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase (Decrease) in Receivables of -$316.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for the quarter ending 2026-06-30 was -$8.04M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for the quarter ending 2026-03-31 was $7.72M, a 102.86% increase year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for the quarter ending 2025-12-31 was $10.73M, a 17483.61% increase year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for the quarter ending 2025-09-30 was -$9.36M, a 185.42% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for fiscal 2025 was $4.91M, a 60.58% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for fiscal 2024 was $12.46M, a 17.43% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for fiscal 2023 was $10.61M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in receivables for fiscal 2022 was -$1.93M, a 112.50% decline from fiscal 2021.
| Period end | Increase (Decrease) in Receivables 3 month | Increase (Decrease) in Receivables 6 month | Increase (Decrease) in Receivables 9 month | Increase (Decrease) in Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$316.00K 10-Q · filed 2026-08-06 | $10.41M derived: sum of 3 quarters · filed 2026-08-06 | $1.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.72M 10-Q · filed 2026-05-07 | $18.45M derived: sum of 2 quarters · filed 2026-05-07 | $9.08M derived: sum of 3 quarters · filed 2026-05-07 | $8.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.36M derived: sum of 2 quarters · filed 2026-02-26 | $1.10M derived: sum of 3 quarters · filed 2026-08-06 | $4.91M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$9.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$9.62M derived: sum of 2 quarters · filed 2026-08-06 | -$5.82M 10-Q · filed 2025-11-04 | -$5.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.55M 10-Q · filed 2026-08-06 | $3.61M derived: sum of 3 quarters · filed 2026-08-06 | $14.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.81M 10-Q · filed 2026-05-07 | $3.87M derived: sum of 2 quarters · filed 2026-05-07 | $14.83M derived: sum of 3 quarters · filed 2026-05-07 | $11.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.02M derived: sum of 2 quarters · filed 2026-02-26 | $7.63M derived: sum of 3 quarters · filed 2026-02-26 | $12.46M 10-K · filed 2026-02-26 |
| 2024-09-30 | $10.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.57M derived: sum of 2 quarters · filed 2025-11-04 | $12.39M 10-Q · filed 2025-11-04 | -$1.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.43M 10-Q · filed 2025-07-31 | -$12.42M derived: sum of 3 quarters · filed 2026-02-26 | $6.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $4.82M 10-Q · filed 2025-05-12 | -$9.04M derived: sum of 2 quarters · filed 2026-02-26 | $9.41M derived: sum of 3 quarters · filed 2026-02-26 | $9.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$13.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.59M derived: sum of 2 quarters · filed 2026-02-26 | $5.05M derived: sum of 3 quarters · filed 2026-02-26 | $10.61M 10-K · filed 2026-02-26 |
| 2023-09-30 | $18.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $18.90M derived: sum of 2 quarters · filed 2024-11-07 | $24.46M 10-Q · filed 2024-11-07 | -$3.82M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $457.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $6.02M 10-Q · filed 2024-08-01 | -$22.27M derived: sum of 3 quarters · filed 2025-02-27 | $1.33M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.56M 10-Q · filed 2024-05-02 | -$22.72M derived: sum of 2 quarters · filed 2025-02-27 | $874.00K derived: sum of 3 quarters · filed 2025-02-27 | -$1.35M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$28.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.68M derived: sum of 2 quarters · filed 2025-02-27 | -$6.91M derived: sum of 3 quarters · filed 2025-02-27 | -$1.93M 10-K · filed 2025-02-27 |
| 2022-09-30 | $23.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $21.37M derived: sum of 2 quarters · filed 2023-11-02 | $26.36M 10-Q · filed 2023-11-02 | $31.96M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | -$2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.76M 10-Q · filed 2023-08-03 | $8.36M derived: sum of 3 quarters · filed 2024-02-15 | $13.76M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $4.99M 10-Q · filed 2023-05-04 | $10.59M derived: sum of 2 quarters · filed 2024-02-15 | $15.98M derived: sum of 3 quarters · filed 2024-02-15 | $19.21M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $11.00M derived: sum of 2 quarters · filed 2024-02-15 | $14.23M derived: sum of 3 quarters · filed 2024-02-15 | $15.41M 10-K · filed 2024-02-15 |
| 2021-09-30 | $5.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $8.63M derived: sum of 2 quarters · filed 2022-11-03 | $9.81M 10-Q · filed 2022-11-03 | $10.46M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.42M 10-Q · filed 2022-08-04 | $5.07M derived: sum of 3 quarters · filed 2023-02-28 | $4.91M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $1.19M 10-Q · filed 2022-05-10 | $1.84M derived: sum of 2 quarters · filed 2023-02-28 | $1.68M derived: sum of 3 quarters · filed 2023-02-28 | $1.84M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $488.00K derived: sum of 2 quarters · filed 2023-02-28 | $650.00K derived: sum of 3 quarters · filed 2023-02-28 | $650.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $162.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $162.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $151.00K 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $108.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |